Cargando…
Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803798/ https://www.ncbi.nlm.nih.gov/pubmed/35038002 http://dx.doi.org/10.1007/s00406-021-01378-1 |
| _version_ | 1784642947280535552 |
|---|---|
| author | Leucht, Stefan Davis, John M. |
| author_facet | Leucht, Stefan Davis, John M. |
| author_sort | Leucht, Stefan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8803798 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88037982022-02-02 Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia Leucht, Stefan Davis, John M. Eur Arch Psychiatry Clin Neurosci Editorial Springer Berlin Heidelberg 2022-01-17 2022 /pmc/articles/PMC8803798/ /pubmed/35038002 http://dx.doi.org/10.1007/s00406-021-01378-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Editorial Leucht, Stefan Davis, John M. Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia |
| title | Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia |
| title_full | Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia |
| title_fullStr | Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia |
| title_full_unstemmed | Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia |
| title_short | Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia |
| title_sort | which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803798/ https://www.ncbi.nlm.nih.gov/pubmed/35038002 http://dx.doi.org/10.1007/s00406-021-01378-1 |
| work_keys_str_mv | AT leuchtstefan whichfirstgenerationantipsychoticsshouldberepurposedforthetreatmentofschizophrenia AT davisjohnm whichfirstgenerationantipsychoticsshouldberepurposedforthetreatmentofschizophrenia |